<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119229">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01757470</url>
  </required_header>
  <id_info>
    <org_study_id>D4200L00059</org_study_id>
    <nct_id>NCT01757470</nct_id>
  </id_info>
  <brief_title>Vandetanib Risk Minimisation Effectiveness</brief_title>
  <official_title>Effectiveness of Risk Minimisation Interventions for Vandetanib in Canada</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yolarx Consultants, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <authority>Canada: Health Canada</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Effectiveness of risk minimisation interventions for vandetanib in Canada
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      As part of the new drug approval process in Canada, AstraZeneca has committed to Health
      Canada to conduct a Drug Utilization Study among patients recently treated with CAPRELSA
      (vandetanib) and a Knowledge and Understanding Survey among the prescribing physicians to
      determine whether the product monograph, communication plan, and educational material
      developed by AstraZeneca Canada for vandetanib are adequate to provide knowledge about the
      potential risks associated with this product, and if other medications taken concomitantly
      with vandetanib  are managed adequately.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Knowledge and Understanding Survey: Knowledge of the key safety issues pertaining to vandetanib</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>QT prolongation/Torsades de Pointes, diarrhea, rash and other skin reactions- adequate or inadequate for each safety issue (defined by correct response).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - duration of treatment at baseline</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Discontinuation, interruption, continuous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - duration of treatment at 3 months</measure>
    <time_frame>At 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Discontinuation, interruption, continuous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - duration of treatment at 6 months</measure>
    <time_frame>At 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Discontinuation, interruption, continuous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - duration of treatment at 12 months</measure>
    <time_frame>At 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Discontinuation, interruption, continuous</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - dosage at baseline</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - dosage at 3 months</measure>
    <time_frame>At 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - dosage at 6 months</measure>
    <time_frame>At 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Use of vandetanib - dosage at 12 months</measure>
    <time_frame>At 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Concomitant use of QT-prolonging drugs at baseline</measure>
    <time_frame>At baseline</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 3 months</measure>
    <time_frame>At 3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 6 months</measure>
    <time_frame>At 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drug Utilisation Study: Concomitant use of QT-prolonging drugs at 12 months</measure>
    <time_frame>At 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Dichotomous variable - yes/no + total number of concomitant QT-prolonging drugs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Knowledge and Understanding Survey: Practice characteristics</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Main geographical location, average days devoted to patient care, total number of medullary thyroid cancer patients followed up to date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge and Understanding Survey: Previous exposure to vandetanib safety concerns other than product monograph or mandatory online training</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participation in a trial on vandetanib, giving CME conferences, member of a data safety monitoring board.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knowledge and Understanding Survey: Sources of information on key safety messages for vandetanib</measure>
    <time_frame>2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Product monograph, online training, Dear Healthcare Professional letter sent by AstraZeneca, company's sales forces, continuing medical education, conferen.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Medullary Thyroid Cancer</condition>
  <arm_group>
    <arm_group_label>Caplresa Patient</arm_group_label>
    <description>All patients treated with Caprelsa in Canada and participating in the restricted distribution programme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Caplresa Prescriber</arm_group_label>
    <description>All physicians having prescribed at least one dose of Caprelsa and registered as a certified prescriber of Caprelsa in Canada.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Convenience sample for patients and physicians
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - N/A (all patients taking Caprelsa and all prescribers will be contacted for
        participation).

        Exclusion Criteria: - N/A
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yola Moride, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Montréal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 31, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>effectiveness of risk mitigation,</keyword>
  <keyword>knowledge and understanding survey,</keyword>
  <keyword>drug utilisation study,</keyword>
  <keyword>post marketing committments</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
